To include your compound in the COVID-19 Resource Center, submit it here.

Switching scleroderma

How Fibrocell is controlling collagenase to treat localized scleroderma

While existing treatment options for localized scleroderma target inflammation, Fibrocell Science Inc. (NASDAQ:FCSC) and partner Intrexon Corp. (NYSE:XON) plan to enter the clinic next half with FCX-013, a therapy that could reverse fibrosis in patients with moderate to severe disease.

Read the full 403 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE